Global Nonalcoholic Steatohepatitis (NASH) Treatment Market by Phase III Pipeline, Trends and Forecast to 2025, New Report by iHealthcareAnalyst, Inc.
Nonalcoholic Steatohepatitis Treatment Market by Phase III Drugs in Pipeline (Obeticholic Acid, Aramchol, Saroglitazar, and Elafibranor) 2017-2025
Maryland Heights, MO, May 06, 2017 --(PR.com)-- Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a buildup of fat in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease. Non-alcoholic fatty liver disease (NAFLD) is one of the causes of fatty liver, occurring when fat is deposited (steatosis) in the liver due to causes other than excessive alcohol use. Nonalcoholic fatty liver disease (NAFLD) gradually is recognized as a common reason of chronic liver disease. NAFLD spans a spectrum of clinicopathologic entities from simple hepatic steatosis to nonalcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma. Nearly 10% to 20% of the general population affected by NAFLD suffers from NASH. Therefore, the diagnosis methods for NAFLD helps in the prediction of NASH occurrence. The diagnosis methods include evaluation of liver enzymes, hepatic imaging and liver biopsy.
Browse Nonalcoholic Steatohepatitis Treatment Market by Phase III Drugs in Pipeline (Obeticholic Acid, Aramchol, Saroglitazar, and Elafibranor) 2017-2025 at https://www.ihealthcareanalyst.com/report/nonalcoholic-steatohepatitis-treatment-market/
The global nonalcoholic steatohepatitis treatment market segmentation is based on phase III drugs in pipeline (Obeticholic Acid, Aramchol, Saroglitazar, and Elafibranor).
The global nonalcoholic steatohepatitis treatment market report provides market size (Revenue USD Million 2014 to 2021), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2021). The global nonalcoholic steatohepatitis treatment market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global nonalcoholic steatohepatitis treatment market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global nonalcoholic steatohepatitis treatment market and included in this report are Pharmaceuticals Inc., Galmed Pharmaceuticals Ltd., GENFIT SA, and Zydus Cadila.
1. Drug Type
1.1 Phase III Drugs
1.1.1 Aramchol (Arachidyl Amido Cholanoic Acid)
1.1.2 Elafibranor
1.1.3 Obeticholic Acid (OCA)
1.1.4 Saroglitazar
1.2 Phase I and II Drugs
2. Geography (Region, Country)
2.1 North America (U.S., Canada)
2.2 Latin America (Brazil, Mexico, Rest of LA)
2.3 Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4 Asia Pacific (Japan, China, India, Rest of APAC)
2.5 Rest of the World
3. Company Profiles
3.1 AstraZeneca plc
3.2 Conatus Pharmaceuticals
3.3 Galmed Pharmaceuticals
3.4 Genfit Sa
3.5 Gilead Sciences Inc.
3.6 Immuron Ltd.
3.7 Intercept Pharmaceuticals Inc.
3.8 Tobira Therapeutics Inc.
3.9 Zydus Cadila
To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/nonalcoholic-steatohepatitis-treatment-market/
About Us
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Website: https://www.ihealthcareanalyst.com
Browse Nonalcoholic Steatohepatitis Treatment Market by Phase III Drugs in Pipeline (Obeticholic Acid, Aramchol, Saroglitazar, and Elafibranor) 2017-2025 at https://www.ihealthcareanalyst.com/report/nonalcoholic-steatohepatitis-treatment-market/
The global nonalcoholic steatohepatitis treatment market segmentation is based on phase III drugs in pipeline (Obeticholic Acid, Aramchol, Saroglitazar, and Elafibranor).
The global nonalcoholic steatohepatitis treatment market report provides market size (Revenue USD Million 2014 to 2021), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2021). The global nonalcoholic steatohepatitis treatment market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global nonalcoholic steatohepatitis treatment market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global nonalcoholic steatohepatitis treatment market and included in this report are Pharmaceuticals Inc., Galmed Pharmaceuticals Ltd., GENFIT SA, and Zydus Cadila.
1. Drug Type
1.1 Phase III Drugs
1.1.1 Aramchol (Arachidyl Amido Cholanoic Acid)
1.1.2 Elafibranor
1.1.3 Obeticholic Acid (OCA)
1.1.4 Saroglitazar
1.2 Phase I and II Drugs
2. Geography (Region, Country)
2.1 North America (U.S., Canada)
2.2 Latin America (Brazil, Mexico, Rest of LA)
2.3 Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4 Asia Pacific (Japan, China, India, Rest of APAC)
2.5 Rest of the World
3. Company Profiles
3.1 AstraZeneca plc
3.2 Conatus Pharmaceuticals
3.3 Galmed Pharmaceuticals
3.4 Genfit Sa
3.5 Gilead Sciences Inc.
3.6 Immuron Ltd.
3.7 Intercept Pharmaceuticals Inc.
3.8 Tobira Therapeutics Inc.
3.9 Zydus Cadila
To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/nonalcoholic-steatohepatitis-treatment-market/
About Us
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Website: https://www.ihealthcareanalyst.com
Contact
iHealthcareAnalyst, Inc.
Ana Aitawa
(314) 500-7508
https://www.ihealthcareanalyst.com/
Ana Aitawa
(314) 500-7508
https://www.ihealthcareanalyst.com/
Contact
Categories